Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 7/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.35 |
| ▸ | ALPL | P05186 | 4/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6265338 | 0.77 | GSK3B (0.48) | CNR1CNR2DPP4ALPLMAPT | |
| SCHEMBL1219591 | 0.72 | CNR1 (0.43) | CNR1CNR2DPP4DPP8IDO1 | |
| SCHEMBL1219180 | 0.71 | CNR1 (0.48) | CNR1CNR2ALPLIDO1SLC6A3 | |
| SCHEMBL10073234 | 0.65 | KMT2A (0.49) | CNR1CNR2IDO1MAPT | |
| SCHEMBL7858859 | 0.64 | ALDH1A1 (0.53) | CNR1CNR2MAPT | |
| SCHEMBL3843873 | 0.64 | NR1H4 (0.54) | CNR1CNR2KDM4EMAPT | |
| SCHEMBL24088778 | 0.62 | ALDH1A1 (0.48) | CNR1CNR2ALPLIDO1KDM4E | |
| SCHEMBL31668899 | 0.62 | ALDH1A1 (0.48) | CNR1CNR2ALPLIDO1KDM4E | |
| SCHEMBL415970 | 0.62 | ABL1 (0.50) | CNR1CNR2KDM4EMAPT | |
| SCHEMBL27634892 | 0.61 | PRKCZ (0.39) | CNR1CNR2DPP4DPP8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1618127-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1608369-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1537099-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004092360-A2 | THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | CHIRON CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004087153-A2 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |